Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2) Active Not Recruiting Phase 3 Trials for Midostaurin (DB06595)

Also known as: Myelodysplastic Syndrome With Excess Blasts-2

IndicationStatusPhase
DBCOND0092771 (Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2))Active Not Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04027309A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive ChemotherapyTreatment